J.W. Cole Advisors Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 87.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 208,645 shares of the biopharmaceutical company's stock after purchasing an additional 97,092 shares during the quarter. J.W. Cole Advisors Inc.'s holdings in Pfizer were worth $5,287,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the company. Clarity Asset Management Inc. purchased a new position in Pfizer during the 4th quarter valued at $27,000. Gould Capital LLC grew its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. North Capital Inc. purchased a new stake in shares of Pfizer in the first quarter worth about $28,000. Bernard Wealth Management Corp. acquired a new position in Pfizer in the 4th quarter worth about $30,000. Finally, Horizon Financial Services LLC acquired a new position in Pfizer in the 1st quarter worth about $35,000. Hedge funds and other institutional investors own 68.36% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on the company. Leerink Partners cut their price target on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. BMO Capital Markets lowered their price target on Pfizer from $36.00 to $30.00 in a report on Thursday, April 17th. Berenberg Bank cut their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a research report on Thursday, May 29th. Bank of America boosted their price target on Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Finally, HSBC decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Pfizer has a consensus rating of "Hold" and a consensus target price of $28.55.
Check Out Our Latest Analysis on PFE
Pfizer Price Performance
PFE stock opened at $24.46 on Monday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $31.54. The firm has a market capitalization of $139.06 billion, a P/E ratio of 17.72, a price-to-earnings-growth ratio of 0.89 and a beta of 0.58. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The firm has a 50 day moving average of $24.07 and a 200-day moving average of $24.71.
Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the firm earned $0.82 earnings per share. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. As a group, sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.03%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is currently 124.64%.
Pfizer Profile
(
Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Stories
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
